Discovery of a potent and selective human AC2 inhibitor based on 7-deazapurine analogues of adefovir
- Bioorg Med Chem. 2023 Nov 15:95:117508. doi: 10.1016/j.bmc.2023.117508.
- 1. Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 16000 Prague 6, Czech Republic; Department of Organic Chemistry, University of Chemistry and Technology Prague, 16628 Prague 6, Czech Republic.
- 2. Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 16000 Prague 6, Czech Republic.
- 3. Borch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
- 4. Borch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA. Electronic address: [email protected].
- 5. Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 16000 Prague 6, Czech Republic. Electronic address: [email protected].
Adefovir based acyclic nucleoside phosphonates were previously shown to modulate Bacterial and, to a certain extent, human adenylate cyclases (mACs). In this work, a series of 24 novel 7-substituted 7-deazaadefovir analogues were synthesized in the form of prodrugs. Twelve analogues were single-digit micromolar inhibitors of Bordetella pertussis Adenylate Cyclase toxin with no cytotoxicity to J774A.1 macrophages. In HEK293 cell-based assays, compound 14 was identified as a potent (IC50 = 4.45 μM), non-toxic, and selective mAC2 inhibitor (vs. mAC1 and mAC5). Such a compound represents a valuable addition to a limited number of small-molecule probes to study the biological functions of individual endogenous mAC isoforms.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Adenylate CyclaseResearch Areas: Infection
-
target: Adenylate CyclaseResearch Areas: Others